You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 5,747,472

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,747,472

Title:	Therapeutic methods for using ARA-G derivatives
Abstract:	6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumour therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.
Inventor(s):	Krenitsky; Thomas Anthony (Chapel Hill, NC), Averett; Devron Randolph (Raleigh, NC), Koszalka; George Walter (Chapel Hill, NC), Wolberg; Gerald (Cary, NC)
Assignee:	Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:	08/456,186
Patent Claims:	1. The method of treating a mammal having lymphocytic leukemia which comprises administering to said mammal an effective treatment amount of the compound 2-amino-6-methoxy-9-(.beta.-D-arabinofuranosyl)-9H-purine. 2. The method of treating a mammal having lymphoma which comprises administering to said mammal an effective treatment amount of the compound 2-amino-6-methoxy-9-(.beta.-D-arabinofuranosyl)-9H-purine. 3. A method for the treatment of mammalian tumors susceptible to inhibition of T-cell growth, said method comprising administering to a mammal having said tumor an effective T-cell growth inhibiting amount of a compound of formula (I) ##STR2## wherein: R.sup.1 is methoxy; or a pharmaceutically acceptable ester or salt thereof. 4. A method for the treatment of T-cell lymphoproliferative disorders in a mammal, said method comprising administering to said mammal an effective T-cell lymphoproliferative disorder treatment amount of a compound of formula (I) ##STR3## R.sup.1 is methoxy; or a pharmaceutically acceptable ester or salt thereof. 5. A method according to claim 4, wherein the T-cell lymphoproliferative disorder is an autoimmune disease. 6. A method according to claim 5, wherein the autoimmune disease is arthritis. 7. A method according to claim 5, wherein the autoimmune disease is insulin dependent diabetes mellitus. 8. A method for the treatment of mammalian tumors susceptible to inhibition of T-cell growth, said method comprising administering to a mammal having said tumor an effective T-cell growth inhibiting amount of 2-amino-6-methoxy-9-(.beta.-D-arabinofuranosyl)-9H-purine or a pharmaceutically acceptable ester or salt thereof. 9. The method of claims 8 wherein said ester is (5-O-acetyl-.beta.-D-arabinofuranosyl)-2-amino-6-methoxy-9-9H-purine. 10. A method for the treatment of T-cell lymphoproliferative disorders in a mammal, said method comprising administering to said mammal an effective T-cell lymphoproliferative disorder treatment amount of 2-amino-6-methoxy-9-(.beta.-D-arabinofuranosyl)-9H-purine or a pharmaceutically acceptable ester or salt thereof. 11. The method of claim 10 wherein said ester is (5-O-acetyl-.beta.-D-arabinofuranosyl)-2-amino-6-methoxy-9-9H-purine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.